Celltrion Files Two Additional Petitions for IPR of Genentech’s Trastuzumab Patents

Goodwin
Contact

Celltrion has filed two additional petitions for inter partes review of Genentech patents related to trastuzumab:  IPR2017-01139, challenging U.S. Patent 6,627,196, and IPR2017-01140, challenging U.S. Patent 7,371,379.  According to the Petitions, the patents are drawn to methods for treating cancer by administering trastuzumab and a chemotherapeutic agent.  Trastuzumab is sold by Genentech under the trade-name Herceptin®.

Celltrion has recently filed three petitions for review of other Genentech patents related to trastuzumab, as we previously reported.

These petitions and other significant documents related to IPRs on biologic patents are collected on our IPR tracker page.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.